 |
|
Ethics of Phase 1 Oncology Studies
Reexamining the Arguments and Data
Manish Agrawal, MD;
Ezekiel J. Emanuel, MD, PhD
JAMA. 2003;290:1075-1082.
Phase 1 oncology trials are critical to improving the treatment of cancer. Critics have raised 2 fundamental ethical challenges about phase 1 cancer research: the paucity of benefits with substantial risks and poor-quality informed consent. Despite 3 decades of controversy about phase 1 oncology research, there is little critical analysis of the arguments or of the data relevant to these questions. Existing but old data reveal that about 5% of patients in phase 1 trials experience shrinkage of their tumor, with a 0.5% mortality rate. In some notable cases, patients in phase 1 trials have been cured or sustained long-term remissions. Limited data suggest that patients in phase 1 trials may have better quality of life than comparable patients receiving supportive care. More important, the risks and benefits of phase 1 trials are not clearly worse than risk-benefit ratios used by the US Food and Drug Administration to approve chemotherapeutic agents for clinical use. The objections based on informed consent are deficiencies of disclosure, understanding, and voluntariness. The available data do not support the claim that disclosure is deficient. Although studies evaluating patient understanding have substantial methodological problems, they demonstrate that more than 70% of patients understand that they may not directly benefit even when they hope they will personally benefit. Finally, a closer look at issues of voluntariness reveals that patients with advanced cancer who participate in phase 1 research may have a different set of values than do critics and are not coerced. Overall, it appears that phase 1 oncology trials satisfy the requirement for a favorable risk-benefit ratio and that patients who enroll provide adequate informed consent.
Author Affiliations: Department of Clinical Bioethics, Warren G. Magnuson Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, Md.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Patients' Decision-Making Process Regarding Participation in Phase I Oncology Research
Agrawal et al.
JCO 2006;24:4479-4484.
ABSTRACT
| FULL TEXT
Rethinking Risk-Benefit Assessment for Phase I Cancer Trials
Joffe and Miller
JCO 2006;24:2987-2990.
FULL TEXT
The Best Guess Approach to Phase I Trial Design
Rosa et al.
JCO 2006;24:206-208.
FULL TEXT
Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Horstmann et al.
NEJM 2005;352:895-904.
ABSTRACT
| FULL TEXT
Risks and Benefits of Phase 1 Oncology Trials, Revisited
Kurzrock and Benjamin
NEJM 2005;352:930-932.
FULL TEXT
The Ethical Conduct of Clinical Research Involving Critically Ill Patients in the United States and Canada: Principles and Recommendations
Am. J. Respir. Crit. Care Med. 2004;170:1375-1384.
FULL TEXT
Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special Imperatives
Anderson et al.
JCO 2004;22:4846-4850.
ABSTRACT
| FULL TEXT
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
Roberts et al.
JAMA 2004;292:2130-2140.
ABSTRACT
| FULL TEXT
Risks and Benefits of Phase 1 Clinical Trials Evaluating New Anticancer Agents: A Case for More Innovation
Chen and Tannock
JAMA 2004;292:2150-2151.
FULL TEXT
An Exploration of Relative Health Stock in Advanced Cancer Patients
Gaskin et al.
Med Decis Making 2004;24:614-624.
ABSTRACT
|
